BeyondSpring's Plinabulin Combo Shows Durable OS, PFS in Post-ICI NSCLC, Outperforming Historical Data
BYSI sits 48% above its 52-week low of $1.175.
Summary
BeyondSpring presented updated positive Phase 2 data for Plinabulin in combination with pembrolizumab and docetaxel for metastatic NSCLC patients who progressed after first-line immune checkpoint inhibitor therapy. The study demonstrated a median Progression-Free Survival of 7.0 months and a 24-month Overall Survival rate of 58.0% (median OS not reached), both significantly outperforming historical docetaxel data. This follows previous positive Phase 3 data for Plinabulin in NSCLC reported in March, and recent Q1 2026 results showing an increased net loss and low cash position. The strong efficacy data in a difficult-to-treat patient population provides significant validation for Plinabulin, the company's lead asset, and could be crucial for its future amidst financial challenges.
At the time of this announcement, BYSI was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71.5M. The 52-week trading range was $1.18 to $3.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.